Fluticasone in mild to moderate atopic dermatitis relapse: A randomized controlled trial


Por: Rubio-Gomis E, Martinez-Mir I, Morales-Olivas FJ, Martorell-Aragones A, Palop-Larrea V, Bernalte-Sesé A, Cerda-Mir JC, Polo-Martín P, Febrer I, Aranda-Grau L, Llosa-Cortes I, Tejedor-Sanz MJ, Julia-Benito JC, Alvarez-de-Laviada-Mulero T, Planelles-Cantarino MV, Apolinar-Valiente E, Loriente-Tur M, Abella-Bazataqui AM, Alvarez-Gonzalez I, Morales-Carpi C, Burches-Greus ME, Ferrer-Bautista AB, Felix-Toledo R, Marmaneu-Laguia D, Garcia-Martinez VE, Beltran-Marques MA and Rodriguez-Gracia B

Publicada: 1 jul 2018
Resumen:
Background: The long-term efficacy of corticosteroids to prevent atopic dermatitis (AD) relapses has partially been addressed in children. This study compared an intermittent dosing regimen of fluticasone propionate (FP) cream 0.05% with its vehicle base in reducing the risk of relapse in children with stabilized AD. Methods A randomized controlled, multicentric, double-blind trial was conducted. Children (2-10 years) with mild/moderate AD (exclusion criteria: > 30% affected body surface area and/or head) were enrolled into an Open-label Stabilization Phase (OSP) of up to 2 weeks on twice daily FP. Those who achieved treatment success entered the Double-blind Maintenance Phase (DMP). They were randomly allocated to receive FP or vehicle twice-weekly on consecutive days for 16 weeks. The primary study endpoint was relapse rate; time to relapse and severity of disease were also studied. Kaplan-Meier estimates were calculated. Results: Fifty-four patients (29 girls) entered the OSP (23 mild AD) and 49 (26 girls) continued into the DMP. Mean age was 5.5 (SD: 2.8) and 5.1 (SD: 2.3) yrs for FP and vehicle groups, respectively. Four patients withdrew from the DMP (two in every group). Patients treated with FP twice weekly had a 2.7 fold lower risk of experiencing a relapse than patients treated with vehicle (relative risk 2.72, SD: 1.28; p = 0.034). FP was also superior to vehicle for delaying time to relapse. Both treatment therapies were well tolerated. Conclusion: This long-term study shows that twice weekly FP provides an effective maintenance treatment to control the risk of relapse in children with AD. (c) 2018 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.

Filiaciones:
Rubio-Gomis E:
 Unidad de Farmacología Clínica, Consorcio Hospital General Universitario de Valencia CHGUV, Valencia, Spain

 Departamento Farmacología, Universitat de Valéncia, Valencia, Spain

Martinez-Mir I:
 Dirección Gerencia-Fundación HGU, CHGUV, Valencia, Spain

Morales-Olivas FJ:
 Departamento Farmacología, Universitat de Valéncia, Valencia, Spain

Martorell-Aragones A:
 Unidad de Alergía Pediátrica, CHGUV, Valencia, Spain

:
 Subdirección Médica Asistencial, Departamento de Salud La Ribera, Alzira, Valencia, Spain

Bernalte-Sesé A:
 Servicio de Farmacia, CHGUV, Valencia, Spain

Cerda-Mir JC:
 Unidad de Alergía Pediátrica, CHGUV, Valencia, Spain

Polo-Martín P:
 Centro de Salud (CS) Barrio de la Luz, Xirivella, Valencia, Spain

Febrer I:
 Servicio Dermatología, CHGUV, Valencia, Spain

Aranda-Grau L:
 Centro de Atención Primaria de Pobla de Vallbona, Valencia, Spain

Llosa-Cortes I:
 CS Monserrat, Valencia, Spain

Tejedor-Sanz MJ:
 CS Torrente II, Valencia, Spain

Julia-Benito JC:
 CS Alzira, Valencia, Spain

Alvarez-de-Laviada-Mulero T:
 Centro de Salud (CS) Barrio de la Luz, Xirivella, Valencia, Spain

Planelles-Cantarino MV:
 CS Paiporta, Valencia, Spain

Apolinar-Valiente E:
 CS Torrente I, Valencia, Spain

Loriente-Tur M:
 CS Alacuas, Valencia, Spain

Abella-Bazataqui AM:
 Centro de Atención Primaria de Pobla de Vallbona, Valencia, Spain

Alvarez-Gonzalez I:
 CS Burjasot II, Valencia, Spain

Morales-Carpi C:
 CS Picasent, Valencia, Spain

Burches-Greus ME:
 CS Xirivella, Valencia, Spain

Ferrer-Bautista AB:
 CS Paiporta, Valencia, Spain

Felix-Toledo R:
 Unidad de Alergía Pediátrica, CHGUV, Valencia, Spain

Marmaneu-Laguia D:
 CS Alacuas, Valencia, Spain

Garcia-Martinez VE:
 CS Alacuas, Valencia, Spain

Beltran-Marques MA:
 CS Torrente I, Valencia, Spain

Rodriguez-Gracia B:
 CS Auxiliar El Vedat de Torrent, Valencia, Spain
ISSN: 03010546





ALLERGOLOGIA ET IMMUNOPATHOLOGIA
Editorial
ELSEVIER DOYMA SL, TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN, España
Tipo de documento: Article
Volumen: 46 Número: 4
Páginas: 378-384
WOS Id: 000437812300010
ID de PubMed: 29373242
imagen Open Access

FULL TEXT

imagen Published Version CC BY-NC 4.0

MÉTRICAS